Status:
UNKNOWN
Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer
Lead Sponsor:
West China Hospital
Collaborating Sponsors:
GeneCast Biotechnology Co., Ltd.
Sichuan Provincial People's Hospital
Conditions:
Lung Cancer
Eligibility:
All Genders
Brief Summary
This study aims to promote the rational use of liquid biopsy in the clinical detection of lung cancer. Lung cancer is a malignant tumor with high morbidity and mortality worldwide. The incidence of lu...
Detailed Description
Lung cancer is a malignant tumor with high morbidity and mortality worldwide. The incidence and mortality of lung cancer in China have topped the list of malignant tumors since 2010.Early diagnosis an...
Eligibility Criteria
Inclusion
- Patients with stage I-III lung cancer who are eligible for surgery(with no restriction of age, gender, or smoking history).
- ECOG score:0-1.
- Patients in the group will be allowed to collect whole blood or tissue samples at specific time points.
- Patients will be regularly tested according to the doctor's advice.
- Signed informed consent.
Exclusion
- The tumor manifests as pure GGO on chest CT scan.
- Patients for surgical biopsy.
- Patients with serious mental disease.
- Surgery is contraindicated for any reason.
Key Trial Info
Start Date :
September 27 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03317080
Start Date
September 27 2017
End Date
September 1 2023
Last Update
October 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041